Tanya M Wildes, Msci

List of Publications by Year
in descending order

183 papers	4,490 citations	126858 33 h-index	128225 60 g-index
185 all docs	185 docs citations	185 times ranked	5321 citing authors

#	Article	IF	Citations
1	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 2020, 136, 936-945.	0.6	436
2	Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet, The, 2021, 398, 1894-1904.	6.3	250
3	Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. Ca-A Cancer Journal for Clinicians, 2021, 71, 78-92.	157.7	230
4	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1228-1263.	0.8	190
5	Systematic review of falls in older adults with cancer. Journal of Geriatric Oncology, 2015, 6, 70-83.	0.5	129
6	Time to Stop Saying Geriatric Assessment Is Too Time Consuming. Journal of Clinical Oncology, 2017, 35, 2871-2874.	0.8	121
7	Senior Adult Oncology, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 82-126.	2.3	116
8	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. American Journal of Hematology, 2019, 94, 1176-1184.	2.0	112
9	Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. Journal of Geriatric Oncology, 2013, 4, 227-234.	0.5	108
10	Senior Adult Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 162-209.	2.3	105
11	Predicting Geriatric Falls Following an Episode of Emergency Department Care: A Systematic Review. Academic Emergency Medicine, 2014, 21, 1069-1082.	0.8	105
12	Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 840-846.	2.0	85
13	NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1357-1370.	2.3	82
14	Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology, 2016, 58, 41-48.	0.8	78
15	Racial disparities in treatment use for multiple myeloma. Cancer, 2017, 123, 1590-1596.	2.0	77
16	Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. Journal of the American Geriatrics Society, 2016, 64, 1988-1995.	1.3	72
17	Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2021, 39, 608-618.	0.8	72
18	Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life. Cancer, 2014, 120, 3994-4002.	2.0	66

#	Article	IF	Citations
19	Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. Journal of Geriatric Oncology, 2019, 10, 479-485.	0.5	64
20	Multiple Myeloma in the Older Adult: Better Prospects, More Challenges. Journal of Clinical Oncology, 2014, 32, 2531-2540.	0.8	61
21	Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. Journal of Geriatric Oncology, 2016, 7, 293-304.	0.5	58
22	Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treatment Reviews, 2017, 57, 58-66.	3.4	54
23	Predictors of chemotherapy dose reduction at first cycle in patients age 65years and older with solid tumors. Journal of Geriatric Oncology, 2015, 6, 133-140.	0.5	48
24	Geriatric assessment as predictors of hospital readmission in older adults with cancer. Journal of Geriatric Oncology, 2015, 6, 254-261.	0.5	48
25	Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 128-136.	2.3	47
26	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. Journal of Geriatric Oncology, 2015, 6, 211-218.	0.5	47
27	Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leukemia and Lymphoma, 2015, 56, 2643-2649.	0.6	47
28	Gaps in nutritional research among older adults with cancer. Journal of Geriatric Oncology, 2016, 7, 281-292.	0.5	47
29	Geriatric Assessment in Older Adults with Multiple Myeloma. Journal of the American Geriatrics Society, 2019, 67, 987-991.	1.3	42
30	Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial. Clinical Cancer Research, 2017, 23, 2186-2194.	3.2	37
31	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. Blood, 2019, 134, 691-691.	0.6	37
32	Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma. Oncologist, 2013, 18, 1074-1079.	1.9	36
33	High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Bone Marrow Transplantation, 2015, 50, 1075-1082.	1.3	36
34	Approach to the Older Adult With Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 500-518.	1.8	36
35	Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 219-224.	0.2	34
36	Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States. Journal of Geriatric Oncology, 2020, 11, 753-760.	0.5	34

#	Article	IF	Citations
37	A phase 2 trial of induction nabâ€paclitaxel and cetuximab given with cisplatin and 5â€fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer, 2013, 119, 766-773.	2.0	31
38	Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. Pain, 2019, 160, 1835-1846.	2.0	30
39	Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. Biology of Blood and Marrow Transplantation, 2020, 26, 2335-2345.	2.0	28
40	Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	1.0	27
41	Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 106.	1.2	27
42	Falls in older adults with cancer: an updated systematic review of prevalence, injurious falls, and impact on cancer treatment. Supportive Care in Cancer, 2021, 29, 21-33.	1.0	27
43	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	7.7	26
44	Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. Journal of Geriatric Oncology, 2020, 11, 764-768.	0.5	26
45	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood, 2021, 138, 387-400.	0.6	26
46	Management of multiple myeloma in older adults: Gaining ground with geriatric assessment. Journal of Geriatric Oncology, 2017, 8, 1-7.	0.5	25
47	Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status. Blood, 2014, 124, 555-555.	0.6	24
48	Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. Supportive Care in Cancer, 2018, 26, 3563-3570.	1.0	23
49	Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEERâ€Medicare database. Cancer, 2020, 126, 808-813.	2.0	23
50	Fall-risk prediction in older adults with cancer: an unmet need. Supportive Care in Cancer, 2016, 24, 3681-3684.	1.0	22
51	Frailty in Older Adults With Multiple Myeloma: A Study of US Veterans. JCO Clinical Cancer Informatics, 2020, 4, 117-127.	1.0	21
52	The benefit of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is independent of age and comorbidity. Journal of Geriatric Oncology, 2010, 1, 48-56.	0.5	20
53	Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. Oral Oncology, 2014, 50, 895-900.	0.8	20
54	Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists. Leukemia and Lymphoma, 2021, 62, 387-398.	0.6	20

#	Article	IF	Citations
55	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. Blood, 2021, 138, 79-79.	0.6	20
56	A comparison of three different approaches to defining frailty in older patients with multiple myeloma. Journal of Geriatric Oncology, 2020, 11, 311-315.	0.5	19
57	Nabâ€paclitaxelâ€based compared to docetaxelâ€based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. Cancer Medicine, 2015, 4, 481-489.	1.3	18
58	nab -Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. Oral Oncology, 2016, 61, 1-7.	0.8	18
59	Geriatric assessment factors are associated with mortality after hospitalization in older adults with cancer. Supportive Care in Cancer, 2016, 24, 4807-4813.	1.0	18
60	Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. Hematology American Society of Hematology Education Program, 2018, 2018, 88-96.	0.9	18
61	Fighting for the integration of geriatric principles into oncology. Journal of Geriatric Oncology, 2018, 9, 705-706.	0.5	18
62	Dasatinib in relapsed or plateau-phase multiple myeloma. Leukemia and Lymphoma, 2009, 50, 137-140.	0.6	17
63	Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. Therapeutic Advances in Hematology, 2014, 5, 3-12.	1.1	17
64	Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 285-289.	0.2	17
65	A comprehensive approach to therapy of haematological malignancies in older patients. Lancet Haematology,the, 2021, 8, e840-e852.	2.2	17
66	Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Transplantation and Cellular Therapy, 2022, 28, 294-302.	0.6	17
67	Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 98-104.e1.	0.2	16
68	Review of perioperative falls. British Journal of Anaesthesia, 2016, 117, 720-732.	1.5	15
69	Falls in older adults with multiple myeloma. European Journal of Haematology, 2018, 100, 273-278.	1.1	15
70	Preventing Treatment-Related Functional Decline: Strategies to Maximize Resilience. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 415-431.	1.8	15
71	Autologous stem cell transplant in older patients (ageâ€‰â‰¥â€‰65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology, 2020, 11, 93-99.	0.5	15
72	Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 647-651.	0.2	15

#	Article	IF	Citations
73	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. JAMA Oncology, 2021, 7, 609.	3.4	15
74	Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 1153-1154.	2.0	14
75	Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 488-496.e6.	0.2	14
76	A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2019, 25, 3776-3783.	3.2	14
77	SIOG guidelines- essential for good clinical practice in geriatric oncology. Journal of Geriatric Oncology, 2019, 10, 196-198.	0.5	14
78	Educating healthcare providers in geriatric oncology â€“ A call to accelerate progress through identifying the gaps in knowledge. Journal of Geriatric Oncology, 2020, 11, 1023-1027.	0.5	14
79	Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e152-e159.	0.2	14
80	Drug development for recurrent and refractory classical Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 529-540.	0.6	13
81	A prospective trial comparing FDG â€•PET / CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. Cancer Medicine, 2014, 3, 1493-1501.	1.3	13
82	The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leukemia and Lymphoma, 2014, 55, 337-341.	0.6	12
83	nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. Oral Oncology, 2017, 72, 26-31.	0.8	12
84	Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. JCO Clinical Cancer Informatics, 2017, 1, 1-8.	1.0	12
85	Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions. JCO Oncology Practice, 2020, 16, e92-e99.	1.4	12
86	The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. Journal of Geriatric Oncology, 2020, 11, 1274-1278.	0.5	12
87	DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Annals of Hematology, 2020, 99, 1041-1048.	0.8	12
88	Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. Journal of Geriatric Oncology, 2021, 12, 508-514.	0.5	12
89	Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma. Ecancermedicalscience, 2014, 8, 480.	0.6	11
90	Simplified frailty assessment tools: are we really capturing frailty or something else?. Leukemia, 2020, 34, 1967-1969.	3.3	11

#	Article	IF	Citations
91	A call to action in hematologic disorders: A report from the ASH scientific workshop on hematology and aging. Journal of Geriatric Oncology, 2018, 9, 287-290.	0.5	10
92	Screening for cognitive impairment in older adults with hematological malignancies using the Montreal Cognitive Assessment and neuropsychological testing. Journal of Geriatric Oncology, 2020, 11, 297-303.	0.5	10
93	Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. Journal of Geriatric Oncology, 2020, 11, 1279-1284.	0.5	10
94	Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide . Clinical Interventions in Aging, 2020, Volume 15, 619-633.	1.3	10
95	Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score. Blood, 2018, 132, 141-141.	0.6	10
96	Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. Medical Oncology, 2017, 34, 28.	1.2	9
97	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology, 2017, 11, 338-345.	1.3	9
98	Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. Journal of Geriatric Oncology, 2021, 12, 235-238.	0.5	9
99	Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e714-e721.	0.2	9
100	Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e353-e354.	0.2	7
101	Cost differential associated with hospice use among older patients with multiple myeloma. Journal of Geriatric Oncology, 2020, 11, 88-92.	0.5	7
102	Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the â€œreal worldâ€• Annals of Hematology, 2021, 100, 1261-1266.	0.8	7
103	Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. Journal of Geriatric Oncology, 2021, 12, 499-507.	0.5	7
104	RTOG 0522: Huge Investment in Patients and Resources and No Benefit With Addition of Cetuximab to Radiotherapyâ€”Why Did This Occur?. Journal of Clinical Oncology, 2015, 33, 1223-1224.	0.8	6
105	Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e937-e943.	0.2	6
106	Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study. Haematologica, 2021, 106, 1991-1994.	1.7	6
107	New treatment approaches for older adults with multiple myeloma. Journal of Geriatric Oncology, 2012, 3, 279-290.	0.5	5
108	Tumour boards in geriatric oncology. Age and Ageing, 2018, 47, 168-170.	0.7	5

#	Article	IF	Citations
109	Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. Journal of Geriatric Oncology, 2020, 11, 179-183.	0.5	5
110	Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy. Journal of Geriatric Oncology, 2021, 12, 1233-1239.	0.5	5
111	The Activity and Toxicity of Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma.. Blood, 2007, 110, 1182-1182.	0.6	5
112	Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study. Blood Cancer Journal, 2022, 12, 17.	2.8	5
113	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer Journal, 2022, 12, 63.	2.8	5
114	Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e363-e364.	0.2	4
115	A Mixed-Methods Study of Stem Cell Transplantation Utilization for Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e521-e525.	0.2	4
116	Make time for gait speed: vital to staging the aging. Blood, 2019, 134, 334-336.	0.6	4
117	Circumstances around falls in older adults with Cancer. Journal of Geriatric Oncology, 2021, 12, 91-95.	0.5	4
118	Research priorities on falls in older adults with cancer. Journal of Geriatric Oncology, 2021, 12, 157-159.	0.5	4
119	A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy. Gynecologic Oncology, 2021, 161, 700-704.	0.6	4
120	Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma. Journal of Geriatric Oncology, 2021, 12, 1005-1009.	0.5	4
121	Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 2246-2246.	0.6	4
122	A 54-Year-Old Man With a Rash and Pulmonary Infiltrates. Chest, 2008, 134, 1340-1343.	0.4	3
123	An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?. Drugs and Aging, 2018, 35, 459-465.	1.3	3
124	Geriatric Oncology: Getting Even Better with Age. Journal of the American Geriatrics Society, 2019, 67, 871-872.	1.3	3
125	Returning to life activities after hematopoietic cell transplantation in older adults. Journal of Geriatric Oncology, 2020, 11, 304-310.	0.5	3
126	Characterize, Optimize, and Harmonize: Caring for Older Adults With Hematologic Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e266-e274.	1.8	3

#	Article	IF	Citations
127	Comorbidities Impact Survival in Multiple Myeloma: Analysis of the Veterans Health Administration National Database. Blood, 2012, 120, 760-760.	0.6	3
128	Personalizing Therapy for Older Adults with Lymphoid Malignancies: Options and Obstacles. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e240-e248.	1.8	3
129	Postradiation Osteosarcoma in an Older Prostate Cancer Survivor: Case Study and Literature Review with Emphasis on Geriatric Principles. Case Reports in Oncology, 2013, 6, 250-255.	0.3	2
130	Looking beyond the CRT paradigm: Why induction chemotherapy is worthy of pursuit. Oral Oncology, 2015, 51, 103-104.	0.8	2
131	High dose therapy and autologous hematopoietic stem cell transplantation in septuagenarians with non-Hodgkin lymphoma: Feasible, but for which patients?. Journal of Geriatric Oncology, 2015, 6, 344-345.	0.5	2
132	Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. Drugs and Aging, 2018, 35, 289-302.	1.3	2
133	Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. Bone Marrow Transplantation, 2021, 56, 2016-2018.	1.3	2
134	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. Blood, 2018, 132, 207-207.	0.6	2
135	Geriatric Assessment in Older Adults with Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 1286-1286.	0.6	2
136	Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. Blood, 2015, 126, 3200-3200.	0.6	2
137	Integrating a Touchscreen-Based Assessment and Screening Tool for Adults with Multiple Myeloma. Blood, 2016, 128, 2373-2373.	0.6	2
138	The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant. Blood, 2016, 128, 3563-3563.	0.6	2
139	Psoas Cross-Sectional Area As Radiographic Measure Of Sarcopenia Does Not Predict Overall Survival In Multiple Myeloma. Blood, 2013, 122, 5326-5326.	0.6	2
140	Emerging therapies for multiple myeloma: Application in older adults. Journal of Geriatric Oncology, 2017, 8, 413-416.	0.5	1
141	Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1188-1190.	1.3	1
142	A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Leukemia and Lymphoma, 2021, 62, 3043-3046.	0.6	1
143	Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population. Blood, 2018, 132, 2245-2245.	0.6	1
144	Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study. Blood, 2018, 132, 5666-5666.	0.6	1

#	Article	IF	Citations
145	Comorbidities Influence Survival in Patients with Multiple Myeloma. Blood, 2011, 118, 3142-3142.	0.6	1
146	Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts) Age 80 and Older: Analysis of the Veterans Health Administration (VHA) National Database. Blood, 2012, 120, 968-968.	0.6	1
147	Presenting Characteristics and Symptom Burden of Newly Diagnosed Older Multiple Myeloma Patients in the Commpass Study. Blood, 2015, 126, 3307-3307.	0.6	1
148	A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Blood, 2016, 128, 3329-3329.	0.6	1
149	Comparison of Outcomes in Elderly Patients with Non-Hodgkins Lymphoma Undergoing High-Dose Chemotherapy to Their Younger Counterparts: Greater Morbidity but No Significant Impact on Overall Survival.. Blood, 2005, 106, 2086-2086.	0.6	1
150	The Senescence-Associated Secretory Phenotype In Multiple Myeloma. Blood, 2013, 122, 5357-5357.	0.6	1
151	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 2456-2456.	0.6	1
152	D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma. Blood, 2018, 132, 2021-2021.	0.6	1
153	Disparities in Healthcare Resource Utilization for Multiple Myeloma. Blood, 2018, 132, 4793-4793.	0.6	1
154	Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma. Blood, 2018, 132, 5627-5627.	0.6	1
155	Analysis of Falls in Older Adults with Multiple Myeloma Undergoing First-Line Therapy. Blood, 2019, 134, 5886-5886.	0.6	1
156	Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment. Blood, 2019, 134, 4774-4774.	0.6	1
157	The Ire of IRE1Î±: Overexpression of IRE1Î± at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1Î± Expression Is Predictive of Therapy Resistance. Blood, 2019, 134, 4351-4351.	0.6	1
158	Decision Making Factors That Influence Treatment Options for an Autologous Stem Cell Transplant for Older Adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods Study. Blood, 2020, 136, 13-13.	0.6	1
159	Outcomes of P16 positive oropharyngeal squamous cell carcinoma treated with surgery and adjuvant IMRT. Journal of Radiation Oncology, 2015, 4, 37-46.	0.7	0
160	Study design for vulnerable older adults with multiple myeloma. Journal of Geriatric Oncology, 2017, 8, 162-164.	0.5	0
161	Geriatric oncology: this must be just like livinâ€™ in paradise. Geriatrics Gerontology and Aging, 2021, 15, .	0.3	0
162	Addition by subtraction. Blood, 2021, 137, 3005-3006.	0.6	0

#	Article	IF	Citations
163	The Demographics and Outcomes of Patients with Multiple Myeloma Dual Refractory to or Intolerant of Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide. Blood, 2012, 120, 4050-4050.	0.6	0
164	Efficacy Of Bortezomib-Based Regimens With Or Without An Immunomodulatory Agent In Older Adults With Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood, 2013, 122, 5580-5580.	0.6	0
165	Front-Line Radiotherapy Is Associated with Shortened Survival in Newly Diagnosed Multiple Myeloma Patients. Blood, 2014, 124, 5696-5696.	0.6	0
166	A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma. Blood, 2014, 124, 4731-4731.	0.6	0
167	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 850-850.	0.6	0
168	The Association of International Staging System (ISS) Stage with Disease and Symptom Burden in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 2115-2115.	0.6	0
169	Variations in Multiple Myeloma Disease Presentation By Race. Blood, 2015, 126, 5618-5618.	0.6	0
170	The Association Between Performance Status and Health-Related Quality of Life. Blood, 2015, 126, 3312-3312.	0.6	0
171	Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma. Blood, 2016, 128, 2349-2349.	0.6	0
172	Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma. Blood, 2017, 130, 862-862.	0.6	0
173	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. Blood, 2018, 132, 1388-1388.	0.6	0
174	The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma. Blood, 2018, 132, 4463-4463.	0.6	0
175	The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients. Blood, 2018, 132, 3439-3439.	0.6	0
176	Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults with Multiple Myeloma to Drive Personalized Treatment Decisions. Blood, 2019, 134, 3443-3443.	0.6	0
177	Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5701-5701.	0.6	0
178	Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies. Blood, 2019, 134, 5819-5819.	0.6	0
179	Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes. Blood, 2020, 136, 30-31.	0.6	0
180	A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma. Blood, 2020, 136, 31-32.	0.6	0

#	Article	IF	Citations
181	Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL). Blood, 2020, 136, 6-7.	0.6	0
182	A Preliminary Assessment of HeterozygousCFHR3-CFHR1Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome. Blood, 2020, 136, 8-9.	0.6	0
183	Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study. Blood, 2020, 136, 1-2.	0.6	0